Dr. Christopher G. Chow, MD
Internal Medicine (Internal Medicine Physician)
18433 Roscoe Blvd, #208
Northridge, CA 91325
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- New York University Medical College - Nlg (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 464
Licensed in California since 2000, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: New York University Medical College - Nlg
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license A73605 (first issued 2000; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northridge Hospital Medical Center Northridge, CA
- Henry Mayo Newhall Hospital Valencia, CA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 464
- Services billed
- 2,823
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,489 | 405 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 550 | 83 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 550 | 83 |
| Established patient office or other outpatient visit, 20-29 minutes | 415 | 243 |
| Ultrasound study of arm and leg arteries | 187 | 173 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 175 | 156 |
| Evaluation of neuropsychological test, first hour | 159 | 148 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 159 | 149 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 142 | 142 |
| Ultrasound of both sides of head and neck blood flow | 107 | 106 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 106 payments worth $2,484 in total to this clinician.
| AbbVie Inc. | $812 |
|---|---|
| Daiichi Sankyo Inc. | $329 |
| Otsuka America Pharmaceutical, Inc. | $202 |
| Ardelyx, Inc. | $123 |
| Lilly USA, LLC | $120 |
| GlaxoSmithKline, LLC. | $101 |
| Amgen Inc. | $86.41 |
| Lundbeck LLC | $83.28 |
| Food and Beverage | $2,484 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 4 companies. The companies reported $1,895,321 in research payments for these studies, mostly to the institutions running them.
- A master protocol to investigate the efficacy and safety of orforglipron once daily in participants with hypertension and obesity or overweight: randomized, double-blind, placebo-controlled trials (attain-hypertension…
Eli Lilly and Company - A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929079 - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company · Active, not recruiting · NCT06260722 - A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company · Completed · NCT05536804 - A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company · Completed · NCT05882045 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A phase 2, parallel-group, double-blind study to investigate the safety and tolerability of LY3549492 compared with placebo in adult participants 55 to 80 years of age and bmi within 22 to 25 kg/M2
Eli Lilly and Company - A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular…
Astellas Pharma Global Development - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.